6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03621046 (ClinicalTrials.gov)	August 20, 2018	6/6/2018	Use of Low-dose Zolpidem in Parkinson's Disease	A Placebo Controlled Double Blind Randomised Controlled Proof of Concept Study of Zolpidem for the Treatment of Motor and Cognitive Deficits in Late-stage Parkinson's	Parkinson Disease	Drug: Zolpidem;Other: Placebo	Aston University	University Hospital Birmingham NHS Foundation Trust	Completed	40 Years	80 Years	All	28	Phase 2	United Kingdom
2	EUCTR2017-004297-34-GB (EUCTR)	31/03/2018	22/06/2018	Use of low-dose zolpidem in Parkinson's.	A placebo controlled double blind randomised controlled proof of concept study of zolpidem for the treatment of motor and cognitive deficits in late-stage Parkinson’s - Zolpidem for treatment of motor and cognitive deficits in Parkinson's	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Stilnoct Product Name: Stilnoct Product Code: 207-3120 INN or Proposed INN: Zolpidem Tartrate	Aston University	NULL	Not Recruiting			Female: yes Male: yes	28	Phase 2	United Kingdom
3	NCT01351168 (ClinicalTrials.gov)	December 2011	9/5/2011	Use of Zolpidem in Parkinson's Disease	A Randomized, Controlled, Double-Blind, Cross-over Study of Zolpidem for Patients With Parkinson's Disease	Parkinson's Disease	Drug: Levodopa;Drug: Zolpidem first dose;Drug: Zolpidem second dose;Drug: sugar pill	Rush University Medical Center	NULL	Withdrawn	30 Years	75 Years	Both	0	Phase 2	United States